Iovance Biotherapeutics Liabilities 2024

Iovance Biotherapeutics Aktienanalyse

What does Iovance Biotherapeutics do?

Iovance Biotherapeutics Inc is a US biotechnology company specializing in the development of personalized immunotherapies for cancer patients. The company was founded in 2007 by Dr. Dendy Engelman and is headquartered in San Carlos, California. Iovance Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Iovance Biotherapeutics's Liabilities

Iovance Biotherapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Iovance Biotherapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Iovance Biotherapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Iovance Biotherapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Iovance Biotherapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Iovance Biotherapeutics Stock

What is the level of liabilities of Iovance Biotherapeutics this year?

Iovance Biotherapeutics has a debt balance of 195.74 M USD this year.

What were the liabilities of Iovance Biotherapeutics compared to the previous year?

The liabilities of Iovance Biotherapeutics have increased by 19.13% increased compared to the previous year.

What are the consequences of high debt for investors of Iovance Biotherapeutics?

High liabilities can pose a risk for investors of Iovance Biotherapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Iovance Biotherapeutics?

Low liabilities mean that Iovance Biotherapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Iovance Biotherapeutics affect the company?

An increase in liabilities of Iovance Biotherapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Iovance Biotherapeutics affect the company?

A decrease in the liabilities of Iovance Biotherapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Iovance Biotherapeutics?

Some factors that can influence the liabilities of Iovance Biotherapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Iovance Biotherapeutics so important for investors?

The liabilities of Iovance Biotherapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Iovance Biotherapeutics take to modify the liabilities?

To change its liabilities, Iovance Biotherapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Iovance Biotherapeutics pay?

Over the past 12 months, Iovance Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Iovance Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Iovance Biotherapeutics?

The current dividend yield of Iovance Biotherapeutics is .

When does Iovance Biotherapeutics pay dividends?

Iovance Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Iovance Biotherapeutics?

Iovance Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Iovance Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Iovance Biotherapeutics located?

Iovance Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Iovance Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Iovance Biotherapeutics from 5/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/3/2024.

When did Iovance Biotherapeutics pay the last dividend?

The last dividend was paid out on 5/3/2024.

What was the dividend of Iovance Biotherapeutics in the year 2023?

In the year 2023, Iovance Biotherapeutics distributed 0 USD as dividends.

In which currency does Iovance Biotherapeutics pay out the dividend?

The dividends of Iovance Biotherapeutics are distributed in USD.